Corcept Therapeutics Incorporated Gross Profit 2011-2026 | CORT

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:

Raw materials and supplies

Wages of production personnel

Depreciation of equipment

Transportation and warehousing costs (if directly related to production)

Importance for business:

Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales.
Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit.
Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry.
Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.

Reasons for a decline in gross profit:

Increase in raw material and supply costs
Rising production expenses
Price reductions due to competition
Decrease in sales volume
Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Corcept Therapeutics Incorporated

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-	301 M	246 M	156 M	79.3 M	48.9 M	25.7 M	10.2 M	3.22 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
301 M	3.22 M	109 M

Quarterly Gross Profit Corcept Therapeutics Incorporated

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	84.5 M	85.1 M	87.3 M	91.4 M	86.5 M	80.1 M	70.9 M	63.6 M	65.3 M	63.1 M	61.2 M	56.5 M	52.1 M	41.8 M	34.8 M	27 M	23.2 M	21.1 M	19.3 M	15.7 M	14.6 M	13 M	11.5 M	9.8 M	8.76 M	7.05 M	5.64 M	4.23 M	4.06 M	2.59 M	1.87 M	1.7 M	1.36 M	1.03 M	827 K	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
91.4 M	827 K	34.8 M

Gross Profit of other stocks in the Biotechnology industry

Issuer	Gross Profit	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	180 M	-	2.43 %	$ 254 M	Germany
Processa Pharmaceuticals PCSA	5 K	$ 2.3	-1.29 %	$ 3.01 M	USA
Aeterna Zentaris AEZS	4.73 M	-	5.93 %	$ 314 M	Canada
Albireo Pharma ALBO	39.2 M	-	-0.23 %	$ 916 M	USA
Alexion Pharmaceuticals, Inc. ALXN	5.52 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	5.51 M	-	2.54 %	$ 160 B	France
Ascendis Pharma A/S ASND	625 M	$ 220.9	2.49 %	$ 5 B	Danmark
Aptinyx APTX	1.56 K	-	-39.0 %	$ 4.57 M	USA
Midatech Pharma plc MTP	-428 K	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1	-	-1.52 %	$ 24.7 M	USA
Amphastar Pharmaceuticals AMPH	356 M	$ 19.57	1.77 %	$ 915 M	USA
Phathom Pharmaceuticals PHAT	153 M	$ 10.47	4.08 %	$ 763 M	USA
Ayala Pharmaceuticals AYLA	90 K	-	-	$ 7.46 M	Israel
AgeX Therapeutics AGE	102 K	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	119 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-32.3 K	-	4.01 %	$ 150 M	Canada
BeiGene, Ltd. BGNE	4.67 B	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	-4.03 M	-	-	$ 546 M	USA
Институт стволовых клеток человека ISKJ	774 M	-	-	-	Russia
Adverum Biotechnologies ADVM	2.32 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	1.27 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	90 K	-	-9.65 %	$ 45.9 M	USA
Pliant Therapeutics PLRX	41.8 K	$ 1.31	2.34 %	$ 80.4 M	USA
Corbus Pharmaceuticals Holdings CRBP	3.94 M	$ 8.31	1.59 %	$ 111 M	USA
Cyclacel Pharmaceuticals CYCC	5.88 K	-	-5.98 %	$ 34.1 M	USA
ChemoCentryx CCXI	64.9 M	-	-	$ 3.74 B	USA
Dynavax Technologies Corporation DVAX	15.8 M	-	-	$ 2.02 B	USA
ProQR Therapeutics N.V. PRQR	313 K	$ 1.58	6.04 %	$ 99.5 M	Niderland
BioDelivery Sciences International BDSI	14 M	-	-4.8 %	$ 255 M	USA
Enochian Biosciences ENOB	37.5 K	-	-	$ 40.5 M	USA
CureVac N.V. CVAC	-10.6 M	-	-	$ 867 M	Germany
Palatin Technologies PTN	73.7 K	$ 21.0	5.79 %	$ 19.5 M	USA
Pulmatrix PULM	12.6 K	$ 2.12	-1.4 %	$ 7.74 M	USA
Arbutus Biopharma Corporation ABUS	-40.6 M	$ 4.53	5.1 %	$ 868 M	Canada